Athira Pharma Inc. Stock Analysis ATHA

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. The company is headquartered in Bothell, Washington and currently employs 26 full-time employees. The company went IPO on 2020-09-18. The firm is focused on developing small molecules to restore neuronal health and slow neurodegeneration. Its approach is designed to modulate the neurotrophic hepatocyte growth factor (HGF) system, which is critical to normal brain function. The Company’s lead drug candidate is ATH-1105. ATH-1105 is a novel, orally available, brain-penetrant small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for the potential treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). ATH-1105 is in development for the potential treatment of ALS. Its ATH-1020 is a novel, orally available small molecule drug candidate designed to positively modulate the neurotrophic HGF system. The company has evaluated several other compounds in preclinical discovery and development for neurodegenerative diseases and other indications.